Stockscreener 앱 받기
6.91
0.00%
0.00
시간 외 거래:
6.91
전일 마감가:
$6.91
열려 있는:
$6.95
하루 거래량:
1.22M
Relative Volume:
0.58
시가총액:
$1.15B
수익:
$246.03M
순이익/손실:
$-32.00M
주가수익비율:
-32.52
EPS:
-0.2125
순현금흐름:
$-16.78M
1주 성능:
+0.00%
1개월 성능:
-12.20%
6개월 성능:
-5.34%
1년 성능:
+93.02%
1일 변동 폭
$6.78
$7.02
1주일 범위
$6.78
$7.26
52주 변동 폭
$3.5101
$10.08
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
명칭
Xeris Biopharma Holdings Inc
전화
844-445-5704
주소
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
6.91 | 1.15B | 246.03M | -32.00M | -16.78M | -0.2125 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-08-12 | 재개 | H.C. Wainwright | Buy |
| 2024-11-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2023-08-28 | 개시 | Craig Hallum | Buy |
| 2022-10-21 | 개시 | Jefferies | Buy |
| 2022-04-28 | 개시 | Craig Hallum | Buy |
| 2021-11-17 | 개시 | SVB Leerink | Outperform |
| 2021-10-29 | 개시 | H.C. Wainwright | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-02-18 | 개시 | Piper Sandler | Overweight |
| 2018-07-16 | 개시 | Jefferies | Buy |
| 2018-07-16 | 개시 | Leerink Partners | Outperform |
| 2018-07-16 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Xeris Biopharma Holdings Inc 주식(XERS)의 최신 뉴스
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Institutional Investors Lost 4.6% Over the Past Week but Have Profited From Longer-term Gains - 富途牛牛
How Xeris’ Diversified Product Portfolio and XP-8121 Progress Could Shape Xeris Biopharma (XERS) Investors - Sahm
Xeris Biopharma (NASDAQ:XERS) and Metagenomi (NASDAQ:MGX) Critical Comparison - Defense World
Xeris Biopharma: Strong Recorlev Momentum And Pipeline Opportunity (XERS) - Seeking Alpha
Y Intercept Hong Kong Ltd Lowers Holdings in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Xeris Biopharma (NASDAQ:XERS) Insider Beth Hecht Sells 16,667 Shares - MarketBeat
Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: Unlocking a 53.91% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Market Trends: What is the implied volatility of Xeris Biopharma Holdings IncTrade Entry Report & Smart Swing Trading Alerts - baoquankhu1.vn
Buy Signal: Can RNST keep up with sector leadersJuly 2025 Market Mood & Growth Focused Entry Reports - baoquankhu1.vn
Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: Exploring a 46% Potential Upside for Investors - DirectorsTalk Interviews
A Look At Xeris Biopharma Holdings (XERS) Valuation After Its Updated 2025 Revenue Outlook - Sahm
Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: Unveiling a 50% Potential Upside in Biotech - DirectorsTalk Interviews
Does Xeris Biopharma (XERS) Boosted 2025 Revenue Guidance Strengthen Its Commercial Momentum Narrative? - simplywall.st
How Investors Are Reacting To Xeris Biopharma (XERS) Raising 2025 Revenue Outlook And Recorlev Momentum - Sahm
Technical Analysis: What are Xeris Biopharma Holdings Incs technical support levels2025 Price Momentum & Smart Investment Allocation Insights - baoquankhu1.vn
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is It Too Late To Consider Xeris Biopharma Holdings (XERS) After Its 133% One-Year Surge? - Yahoo Finance
Assessing Xeris Biopharma Holdings (XERS) Valuation After Strong Recent Shareholder Returns - Yahoo Finance
Is Xeris Biopharma Holdings (XERS) Price Rally Still Justified After Recent Company Updates - Sahm
Why Xeris Biopharma Holdings (XERS) Is Up 7.9% After Raising 2025 Revenue Outlook and Adding Patents - Yahoo Finance
XERS: HC Wainwright & Co. Reiterates Buy Rating with $10.00 Pric - GuruFocus
Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells 15,000 Shares of Stock - MarketBeat
Xeris Biopharma (NASDAQ:XERS) Earns Buy Rating from HC Wainwright - MarketBeat
Published on: 2026-01-13 01:49:04 - ulpravda.ru
Xeris Biopharma (XERS) Exceeds 2025 Revenue Expectations - GuruFocus
Will Xeris Biopharma Holdings Inc. stock outperform tech sector in 20252025 EndofYear Setup & Weekly High Potential Stock Alerts - Улправда
Breakout Move: Is Xeris Biopharma Holdings Inc. stock a smart buy before Fed meetingJuly 2025 Trade Ideas & AI Driven Price Predictions - Улправда
How Xeris Biopharma Holdings Inc. stock benefits from strong dollarJuly 2025 Update & AI Powered Buy and Sell Recommendations - Улправда
Is Xeris Biopharma Holdings Inc. stock positioned well for digital economyBreakout Watch & Smart Allocation Stock Reports - Улправда
Xeris Biopharma expects full-year 2025 revenue above estimates - MSN
Xeris Biopharma (NASDAQ:XERS) Shares Gap UpHere's Why - MarketBeat
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue - BioSpace
Xeris Biopharma Holdings, Inc. Updates Earnings Guidance for the Full-Year 2025 - marketscreener.com
A biotech treating 700 patients is on track for a record revenue year - Stock Titan
Xeris Biopharma director Shannon sells $176k in shares By Investing.com - Investing.com UK
Xeris Biopharma director Shannon sells $176k in shares - Investing.com
Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock - MarketBeat
Xeris Biopharma Holdings, Inc. $XERS Shares Sold by Diversified Trust Co - MarketBeat
This Small Biotech Stock Is Still a Buy After Massive Bottom-Line Gift - TheStreet Pro
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
Xeris Biopharma (NASDAQ:XERS) Trading Down 6.8%Time to Sell? - MarketBeat
Calamos Advisors LLC Makes New Investment in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday - Finviz
Is Xeris Biopharma on the Verge of a Breakthrough? - StocksToTrade
Xeris Biopharma Holdings Inc. (XERS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
XERS FinancialsIncome Statement - Quiver Quantitative
Xeris Biopharma Holdings Inc (XERS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Xeris Biopharma Holdings Inc 주식 (XERS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| McCulloch Kevin | See Remarks |
Jan 08 '26 |
Sale |
8.00 |
15,000 |
120,000 |
1,685,426 |
1.24%
0.19%
자본화:
|
볼륨(24시간):